Influence of APOE ε4 on performance of CSF biomarkers in differentiating clinical Alzheimer's disease

被引:0
|
作者
Wang, Yan [1 ,2 ]
Li, Fangyu [1 ,2 ]
Qin, Qi [1 ,2 ]
Li, Tingting [1 ,2 ]
Wang, Qi [1 ,2 ]
Li, Yan [1 ,2 ]
Li, Ying [1 ,2 ]
Jia, Jianping [1 ,2 ,3 ,4 ,5 ]
机构
[1] Capital Med Univ, Xuanwu Hosp, Innovat Ctr Neurol Disorders, Natl Clin Res Ctr Geriatr Dis, Beijing, Peoples R China
[2] Capital Med Univ, Xuanwu Hosp, Natl Clin Res Ctr Geriatr Dis, Dept Neurol, Beijing, Peoples R China
[3] Capital Med Univ, Clin Ctr Neurodegenerat Dis & Memory Impairment, Beijing, Peoples R China
[4] Capital Med Univ, Beijing Inst Brain Disorders, Ctr Alzheimers Dis, Collaborat Innovat Ctr Brain Disorders, Beijing, Peoples R China
[5] Minist Educ, Key Lab Neurodegenerat Dis, Beijing, Peoples R China
来源
基金
中国国家自然科学基金; 美国国家卫生研究院;
关键词
Alzheimer's disease; Apolipoprotein E; Mild cognitive impairment; Biomarker; Cognitive decline; CEREBROSPINAL-FLUID; TAU; METAANALYSIS; LOCI; BETA;
D O I
10.1016/j.tjpad.2025.100065
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: Apolipoprotein E epsilon 4 (APOE epsilon 4) bring the higher risk of Alzheimer' Disease (AD). It is essential to evaluate whether the diagnostic performances and critical values of cerebrospinal fluid (CSF) biomarkers are influenced by APOE epsilon 4, which has guiding significance for the clinical practical application. Methods: The differences in CSF biomarkers and their performances between APOE epsilon 4 carriers and non-carriers in distinguishing AD, mild cognitive impairment (MCI) and preclinical AD from normal controls (NCs) were analyzed. The receiver operating characteristic (ROC) curves were generated to compare the area under the curve (AUC) between APOE epsilon 4 carriers and non-carriers, as well as the critical values corresponding Youden Index. Results: In a cross sectional convenience sample of 1610 participants, lower A beta 42 and A beta 42/A beta 40 and higher p-Tau 181/A beta 42 in CSF were observed among APOE epsilon 4 carriers than non-carriers in NC, MCI, and AD groups (P< 0.05). The performance of CSF p-tau/A beta 42 in distinguishing MCI from NC among APOE epsilon 4 carriers was superior to non-carriers [AUC: 0.714 (95%CI: 0.673- 0.752) vs 0.600 (95%CI: 0.564- 0.634), P< 0.001], although it was similar in distinguishing AD from NC between APOE epsilon 4 carriers and non-carriers [AUC: 0.874 (95%CI: 0.835-0.906) vs 0.876 (95%CI: 0.843- 0.904)]. In the longitudinal cohort of 254 participants, the association of CSF A beta 42, A beta 42/A beta 40 and p-Tau181/A beta 42 with cognitive decline were stronger in APOE epsilon 4 carriers compared to non-carriers (P< 0.05). Meanwhile, the critical values were different depending on APOE genotype. Discussion: The CSF level of p-Tau181/A beta 42 was significantly different between APOE epsilon 4 carriers and non-carriers at different stages of AD. The results indicate that the performances of CSF biomarkers are influenced by APOE epsilon 4, which should be considered in the practical application.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimer's Disease
    Geijselaers, Stefan L. C.
    Aalten, Pauline
    Ramakers, Inez H. G. B.
    De Deyn, Peter Paul
    Heijboer, Annemieke C.
    Koek, Huiberdina L.
    OldeRikkert, Marcel G. M.
    Papma, Janne M.
    Reesink, Fransje E.
    Smits, Lieke L.
    Stehouwer, Coen D. A.
    Teunissen, Charlotte E.
    Verhey, Frans R. J.
    van der Flier, Wiesje M.
    Biessels, Geert Jan
    JOURNAL OF ALZHEIMERS DISEASE, 2018, 61 (01) : 309 - 320
  • [32] Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimer’s disease
    Kwangsik Nho
    Sungeun Kim
    Emrin Horgusluoglu
    Shannon L. Risacher
    Li Shen
    Dokyoon Kim
    Seunggeun Lee
    Tatiana Foroud
    Leslie M. Shaw
    John Q. Trojanowski
    Paul S. Aisen
    Ronald C. Petersen
    Clifford R. Jack
    Michael W. Weiner
    Robert C. Green
    Arthur W. Toga
    Andrew J. Saykin
    BMC Medical Genomics, 10
  • [33] Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimer's disease
    Nho, Kwangsik
    Kim, Sungeun
    Horgusluoglu, Emrin
    Risacher, Shannon L.
    Shen, Li
    Kim, Dokyoon
    Lee, Seunggeun
    Foroud, Tatiana
    Shaw, Leslie M.
    Trojanowski, John Q.
    Aisen, Paul S.
    Petersen, Ronald C.
    Jack, Clifford R., Jr.
    Weiner, Michael W.
    Green, Robert C.
    Toga, Arthur W.
    Saykin, Andrew J.
    BMC MEDICAL GENOMICS, 2017, 10
  • [34] Influence of age in CSF biomarkers of Alzheimer's disease from control subjects
    Monge-Argiles, J. A.
    Munoz-Ruiz, C.
    Sanchez-Paya, J.
    Montoya-Gutierrez, J.
    Leiva-Santana, C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 : 108 - 108
  • [35] Age and diagnostic performance of Alzheimer disease CSF biomarkers
    Mattsson, N.
    Rosen, E.
    Hansson, O.
    Andreasen, N.
    Parnetti, L.
    Jonsson, M.
    Herukka, S. -K.
    van der Flier, W. M.
    Blankenstein, M. A.
    Ewers, M.
    Rich, K.
    Kaiser, E.
    Verbeek, M. M.
    Rikkert, M. Olde
    Tsolaki, M.
    Mulugeta, E.
    Aarsland, D.
    Visser, P. J.
    Schroeder, J.
    Marcusson, J.
    de Leon, M.
    Hampel, H.
    Scheltens, P.
    Wallin, A.
    Eriksdotter-Jonhagen, M.
    Minthon, L.
    Winblad, B.
    Blennow, K.
    Zetterberg, H.
    NEUROLOGY, 2012, 78 (07) : 468 - 476
  • [36] Alzheimer's disease and CSF biomarkers: key challenges for broad clinical applications
    Mattson, Niklas
    Zetterberg, Henrik
    BIOMARKERS IN MEDICINE, 2009, 3 (06) : 735 - 737
  • [37] Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratios
    Bouwman, Femke H.
    Frisoni, Giovanni B.
    Johnson, Sterling C.
    Chen, Xiaochun
    Engelborghs, Sebastiaan
    Ikeuchi, Takeshi
    Paquet, Claire
    Ritchie, Craig
    Bozeat, Sasha
    Quevenco, Frances-Catherine
    Teunissen, Charlotte
    ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING, 2022, 14 (01)
  • [38] Clinical validity of CSF biomarkers for Alzheimer's disease: necessary indeed, but sufficient?
    Frisoni, Giovanni B.
    Hansson, Oskar
    LANCET NEUROLOGY, 2016, 15 (07): : 650 - 651
  • [39] Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease
    Leuzy, Antoine
    Bollack, Ariane
    Pellegrino, Daniela
    Teunissen, Charlotte E.
    La Joie, Renaud
    Rabinovici, Gil D.
    Franzmeier, Nicolai
    Johnson, Keith
    Barkhof, Frederik
    Shaw, Leslie M.
    Arkhipenko, Alexander
    Schindler, Suzanne E.
    Honig, Lawrence S.
    Moscoso Rial, Alexis
    Scholl, Michael
    Zetterberg, Henrik
    Blennow, Kaj
    Hansson, Oskar
    Farrar, Gill
    ALZHEIMERS & DEMENTIA, 2025, 21 (03)
  • [40] The influence of APOEε4 on the pTau interactome in sporadic Alzheimer's disease
    Thierry, Manon
    Ponce, Jackeline
    Marta-Ariza, Mitchell
    Askenazi, Manor
    Faustin, Arline
    Leitner, Dominique
    Pires, Geoffrey
    Kanshin, Evgeny
    Drummond, Eleanor
    Ueberheide, Beatrix
    Wisniewski, Thomas
    ACTA NEUROPATHOLOGICA, 2024, 147 (01)